Can renal individuals with renal impairment take Claritin?
In a study involving 12 subjects with chronic renal impairment (creatinine clearance < 30 ml/min) both AUC and Cmax increased by approximately 73% for loratadine and by 120% for descarboethoxyloratadine, as compared to 6 subjects with normal renal function (creatinine clearance > 80 ml/min). The mean elimination half-lives of loratadine (7.6 hours) and descarboethoxyloratadine (23.9 hours) were not substantially different from that observed in normal subjects. Hemodialysis does not have an effect on the pharmacokinetics of loratadine or descarboethoxyloratadine in subjects with chronic renal impairment.
